Interrelationship between diabetes mellitus and heart failure: the role of peroxisome proliferator-activated receptors in left ventricle performance

被引:0
作者
Evangelos Oikonomou
Konstantinos Mourouzis
Petros Fountoulakis
Georgios Angelos Papamikroulis
Gerasimos Siasos
Alexis Antonopoulos
Georgia Vogiatzi
Sotiris Tsalamadris
Manolis Vavuranakis
Dimitris Tousoulis
机构
[1] National and Kapodistrian University of Athens Medical School,1st Department of Cardiology, ‘Hippokration’ Hospital
来源
Heart Failure Reviews | 2018年 / 23卷
关键词
Heart failure; Diabetes mellitus; Systolic dysfunction; Diastolic dysfunction; Peroxisome proliferator-activated receptors; Thiazolidinediones;
D O I
暂无
中图分类号
学科分类号
摘要
Heart failure (HF) is a common cardiac syndrome, whose pathophysiology involves complex mechanisms, some of which remain unknown. Diabetes mellitus (DM) constitutes not only a glucose metabolic disorder accompanied by insulin resistance but also a risk factor for cardiovascular disease and HF. During the last years though emerging data set up, a bidirectional interrelationship between these two entities. In the case of DM impaired calcium homeostasis, free fatty acid metabolism, redox state, and advance glycation end products may accelerate cardiac dysfunction. On the other hand, when HF exists, hypoperfusion of the liver and pancreas, b-blocker and diuretic treatment, and autonomic nervous system dysfunction may cause impairment of glucose metabolism. These molecular pathways may be used as therapeutic targets for novel antidiabetic agents. Peroxisome proliferator-activated receptors (PPARs) not only improve insulin resistance and glucose and lipid metabolism but also manifest a diversity of actions directly or indirectly associated with systolic or diastolic performance of left ventricle and symptoms of HF. Interestingly, they may beneficially affect remodeling of the left ventricle, fibrosis, and diastolic performance but they may cause impaired water handing, sodium retention, and decompensation of HF which should be taken into consideration in the management of patients with DM. In this review article, we present the pathophysiological data linking HF with DM and we focus on the molecular mechanisms of PPARs agonists in left ventricle systolic and diastolic performance providing useful insights in the molecular mechanism of this class of metabolically active regiments.
引用
收藏
页码:389 / 408
页数:19
相关论文
共 50 条
  • [31] Peroxisome proliferator-activated receptor-γ agonists for management and prevention of vascular disease in patients with and without diabetes mellitus
    Ríos-Vázquez R.
    Marzoa-Rivas R.
    Gil-Ortega I.
    Kaski J.C.
    American Journal of Cardiovascular Drugs, 2006, 6 (4) : 231 - 242
  • [32] Role of peroxisome proliferator-activated receptors α and γ in mediating the beneficial effects of β-caryophyllene in a rat model of fragile X syndrome
    Rava, Alessandro
    Buzzelli, Valeria
    Feo, Alessandro
    Ascone, Fabrizio
    Di Trapano, Melania
    Schiavi, Sara
    Carbone, Emilia
    Pasquadibisceglie, Andrea
    Polticelli, Fabio
    Manduca, Antonia
    Trezza, Viviana
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2025, 136
  • [33] Regulation of expression and role of peroxisome proliferator-activated receptors (PPARs) in luminal epithelial and stromal cells of the porcine endometrium
    Blitek, Agnieszka
    Szymanska, Magdalena
    THERIOGENOLOGY, 2019, 127 : 88 - 101
  • [34] Mechanism of the anti-platelet effect of natural bioactive compounds: Role of peroxisome proliferator-activated receptors activation
    Fuentes, Eduardo
    Fuentes, Francisco
    Palomo, Ivan
    PLATELETS, 2014, 25 (07) : 471 - 479
  • [35] Molecular nutrition:: regulation of lipid metabolism by peroxisome proliferator activated receptors (PPAR).: Their relatioship to obesity and diabetes mellitus
    Uauy, R
    Martínez, JI
    Rojas, CV
    REVISTA MEDICA DE CHILE, 2000, 128 (04) : 437 - 446
  • [36] Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease
    Tenenbaum, A
    Motro, M
    Fisman, EZ
    Schwammenthal, E
    Adler, Y
    Goldenberg, I
    Leor, J
    Boyko, V
    Mandelzweig, L
    Behar, S
    CIRCULATION, 2004, 109 (18) : 2197 - 2202
  • [37] Comparative analysis of the in vivo angiogenic properties of stable prostacyclin analogs:: a possible role for peroxisome proliferator-activated receptors
    Pola, R
    Gaetani, E
    Flex, A
    Aprahamian, TR
    Bosch-Marcé, M
    Losordo, DW
    Smith, RC
    Pola, P
    JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2004, 36 (03) : 363 - 370
  • [38] Association of the peroxisome proliferator-activated receptor α gene L162V polymorphism with stage C heart failure
    Arias, Teresa
    Beaumont, Javier
    Lopez, Begona
    Zalba, Guillermo
    Beloqui, Oscar
    Barba, Joaquin
    Valencia, Felix
    Jose Gomez-Doblas, Juan
    De Teresa, Eduardo
    Diez, Javier
    JOURNAL OF HYPERTENSION, 2011, 29 (05) : 876 - 883
  • [39] Pioglitazone, a peroxisome proliferator-activated receptor-γ agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction
    Shiomi, T
    Tsutsui, H
    Hayashidani, S
    Suematsu, N
    Ikeuchi, M
    Wen, J
    Ishibashi, M
    Kubota, T
    Egashira, K
    Takeshita, A
    CIRCULATION, 2002, 106 (24) : 3126 - 3132
  • [40] An innovative approach for the treatment of Alzheimer's disease: the role of peroxisome proliferator-activated receptors and their ligands in development of alternative therapeutic interventions
    Luca Piemontese
    Neural Regeneration Research, 2019, 14 (01) : 43 - 45